AKT1 and melanoma: Although treatment with gefitinib and GW5074 did not significantly inhibit the growth of VemR A375 cells (Figure 3F), combined inhibition with gefitinib and GW5074 could markedly reduce the expressions of p-EKR and p-AKT protein (Figure 3G), which indicated that other signaling pathways might be activated to compensate for the inhibition of MAPK and PI3K/AKT pathways to maintain the proliferation of VemR melanoma cells.